Effect of argatroban combined with dual-antibody therapy on acute posterior circulation ischemic stroke
Objective To explore the effect of argatroban combined with dual-antibody therapy on disease control and bleeding events in patients with acute posterior circulation ischemic stroke(aPCI).Methods A total of 98 aPCI patients treated in Langfang Fourth People's Hospital from December 2020 to September 2023 were enrolled in this study and assigned into two groups using random number table method,with 49 in each group.The patients in the control group were treated with dual anti-bacterial drugs while those in the observation group with dual anti-bacterial drugs plus argatroban for 2 weeks.Then the National Institutes of Health Stroke Scale(NIHSS)score,modified Rankin Scale score,the Bartholin Index score,coagulation and bleeding events were compared between the two groups.Results The NIHSS score in the observation group was lower than that in the control((2.26±0.78)vs(3.65±1.03),t=7.531,P<0.05).After treatment,the observation group reported a higher proportion of patients with mRS scores≤2 as compared with the control(53.06%(26/49)vs 32.65%(16/49),χ2=4.167,P<0.05).Additionally,the BI score was significantly higher in the observation group than in the control((81.33±12.36)points vs(68.45±12.02)points,t=5.229,P<0.05).The activated partial thromboplastin time(APTT)and prothrombin time(PT)of the observation group after autism treatment were(34.52±4.68)s and(13.05±2.88)s,respectively,while those of the control group were(33.38±4.23)s and(12.13±2.40)s,respectively.There was no statistically significant difference between the two groups(t=1.265,1.718,P=0.209,0.089).The levels of fibrinogen and D-dimer in the observation group after treatment were(3.02±1.08)g·L-1 and(0.36±0.11)mg·L-1,respectively and they were lower than those in the control((3.58±1.63)g·L-1,(0.70±0.21)mg·L-1)(t=2.005,10.039,both P<0.05).In terms of the incidence of bleeding events,the observation group was 28.57%(14/49)while the control group was 16.33%(8/49).No statistical difference was found between the two groups(χ2=2.110,P=0.146).Conclusion Argatroban combined with dual-antibody therapy can effectively control the condition of aPCI patients without increasing the risk of bleeding,and the its safety is controllable.
NETL
NSTL
万方数据
